Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 12/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12898542 | 1.00 | PRKCQ (0.42) | PRKCQJAK2JAK1JAK3PTK2 | |
| SCHEMBL1475201 | 0.90 | PRKCQ (0.39) | PRKCQJAK2JAK1JAK3PTK2 | |
| SCHEMBL1475204 | 0.90 | PRKCQ (0.39) | PRKCQJAK2JAK1JAK3PTK2 | |
| SCHEMBL12898540 | 0.89 | JAK3 (0.39) | JAK2JAK1JAK3PTK2ALK | |
| SCHEMBL4590742 | 0.89 | JAK3 (0.39) | JAK2JAK1JAK3PTK2ALK | |
| SCHEMBL12898437 | 0.84 | PRKCQ (0.38) | PRKCQPTK2ALKMAPTGAA | |
| SCHEMBL1266682 | 0.84 | PRKCQ (0.38) | PRKCQALKMAPTGAA | |
| SCHEMBL1266680 | 0.84 | PRKCQ (0.38) | PRKCQALKMAPTGAA | |
| SCHEMBL1265304 | 0.82 | PRKCQ (0.39) | PRKCQALKMAPTGAA | |
| SCHEMBL1265307 | 0.82 | PRKCQ (0.39) | PRKCQALKMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | P2RX7, P2RX5, P2RY1 | PRKCQ 2701/4885JAK2 3325/4885JAK1 1500/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | PRKCQ 2139/4885JAK2 2995/4885JAK1 1243/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | PRKCQ 2139/4885JAK2 2995/4885JAK1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.